scholarly journals Case of recurrent refractory nephrotic syndrome in a Japanese boy with COVID‐19

2021 ◽  
Author(s):  
Yoshitaka Watanabe ◽  
Tsuneki Watanabe ◽  
Hirokazu Ikeda
Keyword(s):  
Nephrotic Syndrome ◽  
Refractory Nephrotic Syndrome

Rituximab in refractory nephrotic syndrome

2009 ◽  
Vol 25 (3) ◽  
pp. 461-468 ◽  
Author(s):  
Agnieszka Prytuła ◽  
Kazumoto Iijima ◽  
Koichi Kamei ◽  
Denis Geary ◽  
Errol Gottlich ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Refractory Nephrotic Syndrome

scholarly journals All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome

2021 ◽  
Author(s):  
Mana Kobayashi ◽  
Yutaro Kageyama ◽  
Takashi Ando ◽  
Junko Sakamoto ◽  
Shohji Kimura
Keyword(s):  
Nephrotic Syndrome ◽  
Standard Deviation ◽  
Real World ◽  
Pediatric Patients ◽  
Safety And Efficacy ◽  
The Real ◽  
Post Marketing Surveillance ◽  
Post Marketing ◽  
Refractory Nephrotic Syndrome ◽  
Observation Period

Abstract Background Rituximab is conditionally approved in Japan for use in patients with refractory nephrotic syndrome. To meet the conditions of approval, an all-case post-marketing surveillance study was conducted to confirm the real-world safety and efficacy of rituximab in patients of all ages with refractory nephrotic syndrome. Methods All patients scheduled to receive rituximab treatment for refractory nephrotic syndrome were eligible to register (registration: August 29, 2014 through April 15, 2016); the planned observation period was 2 years from the initiation of rituximab treatment (intravenous infusion, 375 mg/m2 once weekly for four doses). The study was conducted at 227 hospitals throughout Japan. Adverse drug reactions (ADRs) were collected for safety outcomes. The efficacy outcomes were relapse-free period and the degree of growth in pediatric (< 15 years) patients. Results In total, 997 (447 pediatric) patients were registered; 981 (445) were included in the safety analysis set; 852 (402) completed the 2-year observation period; and 810 (429) were included in the efficacy analysis set. Refractory nephrotic syndrome had developed in childhood for 85.0% of patients, and 54.6% were aged ≥15 years. ADRs were observed in 527 (53.7%) patients, treatment-related infection/infestation in 235 (24.0%) patients, and infusion reactions in 313 (31.9%) patients. The relapse-free period was 580 days (95% confidence interval, 511–664). There was a significant change in height standard deviation score (pediatric patients; mean change, 0.093; standard deviation, 0.637; P = 0.009). Conclusion The safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome were confirmed in the real-world setting. Clinical trial registration UMIN000014997.

scholarly journals Possible mechanisms of LDL apheresis for pediatric patients with steroid resistant and refractory nephrotic syndrome

2010 ◽  
Vol 23 (2) ◽  
pp. 154-159
Author(s):  
Hiroaki Ueda ◽  
Yuko Akioka ◽  
Masakazu Miyamura ◽  
Kiyonobu Ishizuka ◽  
Mamiko Suehiro ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Pediatric Patients ◽  
Ldl Apheresis ◽  
Steroid Resistant ◽  
Refractory Nephrotic Syndrome

Comparison of second-line immunosuppressants for childhood refractory nephrotic syndrome: a systematic review and network meta-analysis

2016 ◽  
Vol 65 (1) ◽  
pp. 65-71 ◽  
Author(s):  
Hai-Dong Fu ◽  
Gu-Ling Qian ◽  
Zheng-yang Jiang
Keyword(s):  
Nephrotic Syndrome ◽  
Mycophenolate Mofetil ◽  
Meta Analysis ◽  
Immunosuppressive Agents ◽  
Second Line ◽  
Childhood Nephrotic Syndrome ◽  
Randomized Controlled ◽  
Search Terms ◽  
October 17 ◽  
Refractory Nephrotic Syndrome

Although, most patients respond initially to therapy for nephrotic syndrome, about 70% of patients have a relapse. Currently, there is no consensus about the most appropriate second-line agent in children who continue to suffer a relapse. This network meta-analysis was designed to compare the efficacy and safety of the commonly used immunosuppressive agents in second-line therapeutic agents (ie, cyclophosphamide, cyclosporine, tacrolimus and mycophenolate mofetil) for refractory childhood nephrotic syndrome. MEDLINE, Cochrane, EMBASE and Google Scholar databases were searched until October 17, 2015 using the following search terms: cyclophosphamide, cyclosporine, tacrolimus, mycophenolate mofetil and childhood nephrotic syndrome. Randomized controlled trials, prospective 2-arm studies and cohort studies were included. 7 studies with 391 patients were included. Bayesian network meta-analysis found that treatment with mycophenolate mofetil had the greatest odds of relapse compared with tacrolimus (pooled OR=49.72, 95% credibility interval (CrI) 1.65 to 2483.32), cyclophosphamide (pooled OR=72.05, 95% CrI 1.44 to 13633.33) and cyclosporine (pooled OR=11.42, 95% CrI 1.03 to 131.60). Rank probability analysis found cyclophosphamide was the best treatment with the lowest relapse rate as compared with other treatments (rank probability=0.58), and tacrolimus was ranked as the second best (rank probability=0.38). Our findings support the use of cyclophosphamide and tacrolimus in treating children with relapsing nephrotic syndrome.

scholarly journals Glucose metabolism disorders in children with refractory nephrotic syndrome

2020 ◽  
Vol 35 (4) ◽  
pp. 649-657 ◽  
Author(s):  
Toshiyuki Takahashi ◽  
Takayuki Okamoto ◽  
Yasuyuki Sato ◽  
Asako Hayashi ◽  
Yasuhiro Ueda ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Glucose Metabolism ◽  
Glucose Metabolism Disorders ◽  
Refractory Nephrotic Syndrome
Sign in / Sign up

Export Citation Format

Share Document